Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the full results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract #LBA2). These data were also simultaneously published in the New England Journal of Medicine. This is the first combination regimen with an anti-PD-1/PD-L1 therapy to improve overall survival (OS), progression-free survival (PFS) and objective response rate (ORR(…) Read More »

Exit mobile version